RxDoctor Payments Data

George Bojrab, MD

Interventional Pain Medicine · Fort Wayne, INNPI 1891768537

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 226 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Medtronic accounts for 79.4% of it on its own, with 20 other manufacturers making up the rest.

$6,567in general payments, 2019–2025

Across 226 payments — averaging $29.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$5K
  • Collegium Pharmaceutical, Inc.$427
  • Pfizer$122
  • Almatica Pharma LLC$108
  • Abbott$104
  • Biodelivery Sciences International, Inc.$81
  • plus $512 from 15 others

What the payments were for

  • Food & beverage$6,567100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,567 in reported general payments places this provider in the 65th percentile of 68 interventional pain medicine providers in Indiana.

See all interventional pain medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$402,127
Medicare patients
687
Services billed
47,510

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate106$83,438
OxycontinOxycodone Hcl36$30,164
Tramadol Hcl ErTramadol Hcl255$25,964
Fentanyl249$24,389
Celecoxib714$22,803
Buprenorphine86$18,964
Tramadol Hcl1,586$18,962
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen861$17,662
Gabapentin962$15,199
LyricaPregabalin16$11,939
Diclofenac Sodium720$11,000
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen510$10,954
Morphine Sulfate ErMorphine Sulfate264$10,556
Pregabalin391$9,700
Duloxetine Hcl424$8,380

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$427$83,438106 claims
PfizerLyrica$122$11,93916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 68 interventional pain medicine providers in Indiana.

Other interventional pain medicine in Fort Wayne

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →